 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 04/27/2005 | | | | Nymox Product Recommended in Today's N.Y. Daily News
topic: Tobacco Exposure Tests
April 27, 2005: Nymox's TobacAlert™ product received a positive independent assessment today in the New
York Daily News “Guinea Pig” column titled “Fuming about secondhand smoke? Try this”. |
| 04/25/2005 | | | | Nymox PMA Slated for FDA Advisory Panel Meeting
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
April 25, 2005: Nymox announced
today that it has been informed that the Company's Premarket Approval (PMA) application to
FDA concerning a kit version of the Company's AlzheimAlert™ urine test will be going
forward to a presentation before a panel of the Medical Devices Advisory Committee. This
step follows the submission of further data and analyses by the Company in October and
December 2004 and March 2005. The date for the panel meeting will be confirmed in due
course. |
| 04/14/2005 | | | | Nymox Signs Marketing and Distribution Deal for Alzheimer's Disease Test with KlinLab in Czech Republic
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
April 14, 2005: Nymox announced today that it has entered into a marketing and distribution agreement with KlinLab Ltd., the premier Czech clinical laboratory company, for the marketing and sales
of Nymox's AlzheimAlert™ product. KlinLab Ltd. offers a complete
spectrum of clinical services along with extensive outpatient services to a large network of hospitals and clinics throughout the Czech Republic. |
| 04/05/2005 | | | | Nymox NicAlert™ Successfully Used as Clinical Tool for Expectant Mothers in Nevada
topic: Tobacco Exposure Tests
April 5, 2005: Nymox announced
today that its tobacco exposure testing technology has proven to be a valuable aid for
counseling expectant mothers about the risks posed by tobacco use and exposure to
themselves and their unborn children. Under the direction of the Medical Director, Dr.
Terrence McGaw, MD, and Tamara Baumann, APN RNC, the Washoe Pregnancy Center in Reno,
Nevada, has successfully been using Nymox's NicAlert™ product as a teaching tool and
counseling aid in order to show expectant mothers the level of their tobacco use and
exposure. |
| 03/31/2005 | | | | Deadly E. Coli Bacteria Remains an Important Threat to U.S. Health According to New Study
topic: R&D: E coli and Other Antibacterial Treatments
March 31, 2005: Despite efforts to improve the safety of the
U.S. food supply, outbreaks of potentially deadly E. coli O157 food contamination
remain common according to a new study by researchers at the Centers for Disease Control. Nymox's
proprietary NXC-4720 product for the treatment of potentially fatal E. coli
O157:H7 contamination has proven effective in reducing the level of contamination on fresh
beef by 99% according to laboratory studies. |
| 03/30/2005 | | | | Newly Published Study Shows Growing Medical Acceptance of Statin Drug Usefulness in Treatment of Dementia
topic: Statins and Alzheimer's Disease
March 30, 2005: Nymox's
U.S. and global patent rights and prospects for the use of statin drugs for treating,
preventing or reducing the risk of Alzheimer's disease (AD) in patients at risk for the
disease have been strongly bolstered by newly published study data showing growing
acceptance of the drugs' indications for patients at risk for dementia. Up to half of
clinicians favor the use of statins for treating patients at risk for developing cognitive
impairment and dementia due to vascular risk factors according to a new study published in
the Journal of Neurological Sciences (March 2005; 229-230: 147-150). |
| 03/24/2005 | | | | New Medicare Decision to Cover Smoking Cessation Good News for Nymox
topic: Tobacco Exposure Tests
March 24, 2005: Nymox Pharmaceutical Corporation welcomes
the news that Medicare will cover smoking cessation counseling services for millions of
its beneficiaries who smoke and have been diagnosed with a smoking related disease or are
taking certain drugs affected by tobacco use. |
| 03/23/2005 | | | | Nymox Makes Major Progress in Global Marketing of Company's Proprietary Alzheimer Test
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
March 23, 2005: Nymox Pharmaceutical Corporation continues
to make major progress in the global marketing strategy for the Company's unique urine
testing technology for Alzheimer's disease. |
| 03/22/2005 | | | | Nymox Drug For Benign Prostatic Hyperplasia Holds Promise For Highly Prevalent Problem
topic: R&D: BPH (enlarged prostate) Treatments
March 22, 2005: Nymox reported
today that its lead drug candidate NX-1207 for the treatment of benign prostatic hyperplasia (BPH) shows good promise as a potential first-line treatment for BPH. In two
completed trials in the U.S. to date, the drug has shown highly significant efficacy without significant side effects. The Company's large Phase 2 trial is expected to be completed later this year. |
| 03/17/2005 | | | | Two New Studies Document Dangers of Second Hand Smoke and Fetal Exposure to Maternal Smoking
topic: Tobacco Exposure Tests
March 17, 2005: Two new studies have highlighted the relevance of Nymox's TobacAlert™ product for measuring smoking and second hand smoke exposure. |
|